A practical reference on visceral fat: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-07-19 and is reviewed periodically as new material appears.
A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
监管记录显示，特沙莫瑞林于 2010 年在美国首次获得批准，用于人类免疫缺陷病毒感染相关的脂肪营养不良患者。批准依据来自降低内脏脂肪的临床试验，而非体重或瘦体重的普遍改善。后续出现了不同制剂版本，但其核心适应症保持一致。关于长期心血管结局和死亡率影响，现有证据仍不充分。
在临床研究之外，特沙莫瑞林常被讨论为生长激素分泌促进剂，但这一说法需要限定。它并不等同于生长激素本身，也不属于普通减重药物。部分研究关注其减少腹部脂肪和改善脂质谱的潜力，另一些研究则关注胰岛素抵抗和 IGF-1 升高等信号。这些效应的临床意义仍在评估中，尚未形成统一结论。
特沙莫瑞林是一种合成肽，其序列与人生长激素释放激素的 44 个氨基酸形式相关。它在 N 端带有反式-3-己烯酰基修饰，这一改动可减缓二肽基肽酶 IV 的降解。该化合物属于生长激素释放激素受体激动剂，可刺激垂体释放生长激素。研究文献通常将其归入合成肽类药物，而非小分子化合物。
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | GHRH receptor agonist |
| Residue count | 44 amino acids | N-terminal trans-3-hexenoyl group |
| Approximate mass | About 5.1 kDa | Derived from the peptide sequence |
| Primary target | Pituitary GHRH receptor | Somatotroph cells of the anterior pituitary |
| Downstream marker | IGF-1 | Measured indirectly in circulation |
A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
Tesamorelin binds to growth hormone-releasing hormone receptors on the surface of pituitary somatotroph cells. This binding activates adenylate cyclase, raising intracellular cyclic AMP levels and triggering the release of growth hormone into circulation. The elevated growth hormone then stimulates hepatic production of insulin-like growth factor 1. Because the effect is mediated through the endogenous axis, secretion remains subject to feedback regulation. This distinguishes it from direct growth hormone administration, which bypasses pituitary control entirely.
Clinical investigation has focused on HIV-associated lipodystrophy, a condition in which antiretroviral therapy contributes to abnormal fat distribution. Excess visceral adipose tissue accumulates in the abdomen while peripheral fat may be lost. Tesamorelin was evaluated for reducing this visceral fat depot, with trials measuring changes in abdominal fat by imaging rather than by body weight alone. The rationale rests on the known lipolytic effects of growth hormone. Effects on visceral fat are documented, while long-term outcomes regarding cardiovascular risk remain less clearly established.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, composed of 44 amino acids. It was designed to retain the biological activity of the native hormone while resisting rapid enzymatic degradation. The compound is classified as a growth hormone secretagogue and belongs to the broader family of hypothalamic releasing factors. In research and clinical settings, it is studied for its ability to stimulate pituitary growth hormone release. Its structure includes a modification at the N-terminus that contributes to an extended half-life relative to native growth hormone-releasing hormone.
=== Branched or cross-linked copolymers === For nonlinear or branched copolymers, a prefix indicating the type of non-linearity is added prior to the copolymer naming. Given the wide range of potential branched polymers, if the branching pattern is unknown, the general prefix branch is used. Examples of other prefixes are shown below.
== Further reading == Bishop, Michael; Duben-Engelkirk, Janet L., and Fody, Edward P. (1992). "Chapter 19, Liver Function, Clinical Chemistry Principles, Procedures, Correlations, 2nd Ed." Philadelphia, J.B. Lippincott Company. Miyabara, Yuichi; Tabata, Masako; Suzuki, Junzo; Suzuki, Shizuo (1992). "Separation and sensitive determination of i-urobilin and 1-stercobilin by high-performance liquid chromatography with fluorimetric detection". Journal of Chromatography B: Biomedical Sciences and Applications. 574 (2): 261–265. doi:10.1016/0378-4347(92)80038-R. PMID 1618958. Miyabara, Y.; Sakata, Y.; Suzuki, J.; Suzuki, S. (1994). "Estimation of faecal pollution based on the amounts of urobilins in urban rivers". Environmental Pollution. 84 (2): 117–122. doi:10.1016/0269-7491(94)90093-0. PMID 15091706. Munson-Ringsrud, Karen and Jorgenson-Linné, Jean (1995). "Urinalysis and Body Fluids, a ColorText and Atlas." St. Louis, Mosby. Nelson, L.; David, Cox M.M. (2005). “Chapter 22 – Biosynthesis of Amino Acids, Nucleotides, and Related Molecules”, pp. 856, In Lehninger Principles of Biochemistry. Freeman, New York. pp. 856. Voet, Donald; Voet, Judith G.; Pratt, Charlotte W. (2018-01-23). Voet's Principles of Biochemistry, Global Edition, 5th Edition. Wiley. p. 1200. ISBN 978-1-119-45166-2. Retrieved 2024-02-01.
== College career == In his junior year at Iowa State he made 26 receptions for 330 yards and six touchdowns. However his senior year was marked with numerous injuries. He only recorded six catches and 47 yards over eight games. He suffered from a rare form of muscle cramping causing raised creatine phosphokinase levels which dampened his chances in the 2014 NFL draft. Overall, he recorded 32 catches for 377 yards and 6 touchdowns.
1993/931) Friendly Societies Act 1992 (Transitional and Consequential Provisions and Savings) Regulations 1993 (S.I. 1993/932) Finance Act 1991, section 58, (Commencement No. 3) Regulations 1993 (S.I. 1993/933) Legal Aid in Criminal and Care Proceedings (Costs) (Amendment) Regulations 1993 (S.I. 1993/934) Housing Benefit and Community Charge Benefit (Subsidy) (No. 2) Order 1993 (S.I. 1993/935) Certification Officer (Amendment of Fees) Regulations 1993 (S.I. 1993/936) Further Education (Exclusion of Land from Transfer) (No. 2) Order 1993 (S.I. 1993/937) Land Registry Trading Fund Order 1993 (S.I. 1993/938) Land Registration (Determination of Costs) Order 1993 (S.I. 1993/939) Local Government Administration (Matters Subject to Investigation) Order 1993 (S.I. 1993/940) Local Elections (Variation of Limits of Candidates' Election Expenses) (Northern Ireland) Order 1993 (S.I. 1993/941) Copyright (Application to Other Countries) Order 1993 (S.I. 1993/942) Performances (Reciprocal Protection) (Convention Countries) Order 1993 (S.I. 1993/943) European Communities (Definition of Treaties) (International Railway Tariffs Agreements) Order 1993 (S.I. 1993/944) Insurance Companies (Accounts and Statements) (Amendment) Regulations 1993 (S.I. 1993/946) Patents (Supplementary Protection Certificate for Medicinal Products) (Amendment) Rules 1993 (S.I. 1993/947) Chessington Computer Centre Trading Fund Order 1993 (S.I. 1993/948) Income Tax (Interest Relief) (Qualifying Lenders) Order 1993 (S.I. 1993/949) Capital Gains Tax (Gilt-edged Securities) Order 1993 (S.I.
Sources: en.wikipedia.org
== Formation mechanism == Eukaryote ribosomes are produced and assembled in the nucleolus. Ribosomal proteins enter the nucleolus and combine with the four rRNA strands to create the two ribosomal subunits (one small and one large) that will make up the completed ribosome. The ribosome units leave the nucleus through the nuclear pores and unite once in the cytoplasm for the purpose of protein synthesis.
The third mountain-building event was the Acadian orogeny which occurred between 375 and 359 million years ago. The Acadian orogeny was caused by a series of collisions of pieces of crust from the Avalonia Terrane, sections broken off from continent of Gondwana, with the North American Plate. The collision initiating this orogeny resulted in the closing of the southern Iapetus Ocean and the formation of a high mountain belt. After the Acadian collision took place, Gondwana began to retreat from Laurentia with the newly accreted Avalonian terranes left behind. As Gondwana moved away, a new ocean opened up, the Rheic Ocean, during the Middle to Late Devonian, and subsequently its closure would result in the formation of the Alleghanian orogeny.
Fricasé is a traditional soup in Bolivian cuisine prepared with pork, pork ribs or chicken, hominy, chuño (a freeze-dried potato product) or potatoes, onion, garlic, salt, pepper and spices. It is sometimes consumed as a hangover food, as having a theoretical potential for easing or alleviating symptoms associated with the hangover. Fricasé is a common soup in Bolivia, and is often sold and consumed in the morning. It is a spicy soup that is typically prepared using large chunks of meat, and chuno potatoes are typically used in the Altiplano region of Bolivia. The aji pepper is sometimes used as an ingredient, and bread crumbs are sometimes used to thicken the soup.
== Publications == Active Biological Evolution: Feedback-Driven, Actively Accelerated Organismal and Cancer Evolution , Frank H. Laukien, 2022 ISBN 979-8-9854147-0-7 Origins & Evolution: Evolution of Our Universe and Planet, and the Origins of Life and Meaning Frank H. Laukien, ISBN 979-8985414721
Apart from fluorescence microscopy, SNAP-tag and CLIP-tag have proven useful in the elucidation of numerous biological processes, including the identification of multiprotein complexes using various approaches such as FRET, cross-linking, proximity ligation assay, as well as the purification of insulin secretory granules of distinct age by doing pulse-chase experiments Other application include the measurement of protein half-lives in vivo, and small molecule-protein interactions. SNAP-tag® is a registered trademark of New England Biolabs, Inc. CLIP-tag™ is a trademark of New England Biolabs, Inc.
Sources: en.wikipedia.org
It mirrors the 44-residue form of human growth hormone-releasing hormone. A hexenoyl group on the N-terminal tyrosine distinguishes it from the unmodified hormone. The change is intended to improve resistance to enzymatic breakdown.
The N-terminal modification reduces cleavage by circulating peptidases, so the peptide persists longer than native GHRH. That persistence is the main rationale for the synthetic design. Comparative half-life values in humans are reported in regulatory review documents rather than in general reference literature.
Reductions in visceral adipose tissue have been measured in controlled studies of defined populations. Whether the effect generalizes to other groups and persists after treatment stops is less clear. Longer-term outcome data remain limited.
特沙莫瑞林是国际非专利名称，指一种经过 N 端修饰的生长激素释放激素类似物。它被归类为合成肽，序列与 GHRH(1-44) 密切相关。该名称不指代任何特定品牌或剂型。